SRR6013550
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
- UV_RESPONSE_DN+0.160
- ANGIOGENESIS+0.140
- TNFA_SIGNALING_VIA_NFKB+0.140
- WNT_BETA_CATENIN_SIGNALING+0.140
- KRAS_SIGNALING_UP+0.130
- APICAL_JUNCTION+0.120
- APICAL_SURFACE+0.080
- TGF_BETA_SIGNALING+0.080
Top 10 suppressed
- MYC_TARGETS_V1-0.600
- OXIDATIVE_PHOSPHORYLATION-0.580
- UNFOLDED_PROTEIN_RESPONSE-0.410
- DNA_REPAIR-0.300
- MTORC1_SIGNALING-0.300
- G2M_CHECKPOINT-0.290
- MYC_TARGETS_V2-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- ANDROGEN_RESPONSE-0.280
- E2F_TARGETS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.878 |
| 2 | SRR1313107 | — | F | 0.861 |
| 3 | MBCProject_2661_T2_RNA | — | A | 0.859 |
| 4 | 95d76fd3-540d-4c50-9ea9-b50fe2c37639 | — | — | 0.858 |
| 5 | SRR13311176 | — | — | 0.855 |
| 6 | TCGA-MN-A4N4-01A-12R-A24X-07 | — | cohortA1 | 0.852 |
| 7 | MNG145 | — | — | 0.848 |
| 8 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.847 |
| 9 | TCGA-A2-A4RY-01A-31R-A266-07 | — | A | 0.843 |
| 10 | R116 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.430 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| HYPOXIA | 0.060 | Idelalisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |